At a Glance
- Company: Charles River Laboratories (NYSE: CRL)
- Location: Wilmington, Massachusetts
- Deal value: $145M cash (IQVIA) + performance contingents (GI)
- Focus area: CDMO/cell therapy manufacturing, European discovery
- Next steps: Q2 2026 closings; 2026 revenue -5% to -3.5%
What happened?
Charles River Laboratories signed definitive agreements on 25 February 2026 to divest its CDMO and Cell Solutions businesses to GI Partners, plus certain European Discovery Services assets to IQVIA. The CDMO/Cell units generated $143M in 2025 revenue; European sites added $144M. IQVIA deal brings ~$145M cash plus up to $10M more.
Why does it matter?
Divestitures shed ~7% of revenue but boost margins 100+ bps and non-GAAP EPS by $0.10, refining focus on high-growth core services (RMS, safety assessment). Follows November 2025 pivot announcement amid activist pressure, enhancing efficiency in competitive CRO market.
Who’s behind it?
Charles River, a leading CRO, targets synergistic growth post-sale. Outgoing CEO James Foster cited portfolio optimisation. Buyers: GI Partners (CDMO expertise); IQVIA (discovery expansion).
How was it achieved?
CDMO sites (TN, MD, UK) and CA Cell Solutions focus on cell/gene therapy manufacturing. European assets cover oncology, neuroscience, immunology discovery. Sales primarily contingent for GI; cash-heavy for IQVIA. Closings Q2 2026 pending conditions.
What’s next?
Updated 2026 guidance: revenue down 5.0%-3.5%; organic -1.5% to -0.5%; EPS $10.80-$11.30. Retains 40% discovery revenue; deploys proceeds for core investments.
What are people saying?
CEO Foster: “Refine… portfolio… drive long-term growth, greater efficiency.” Analysts note margin accretion despite revenue hit.